Scientific Papers

In Vitro antibiotic combinations of Colistin, Meropenem, Amikacin, and Amoxicillin/clavulanate against multidrug-resistant Klebsiella pneumonia isolated from patients with ventilator-associated pneumonia | BMC Microbiology


  • Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious Diseases Society of America and the american thoracic society. Clin Infect Dis. 2016;63(5):e61–e111.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Moradi M, Nili F, Nayeri F, Amini E, Esmaeilnia T. Study of characteristics, risk factors and outcome for Ventilator Associated Pneumonia in neonatal intensive care unit patient. Tehran Univ Med J. 2013;71(6).

  • Kalanuria AA, Mirski M, Ziai W. Ventilator-associated pneumonia in the ICU. Annual Update in Intensive Care and Emergency Medicine. 2014;2014:65–77.


    Google Scholar
     

  • Selina F, Talha KA, Islam A, Hasan Z, Hyder M, Selvapandian S. Organisms associated with ventilator associated pneumonia (VAP) in intensive care units (ICU). J Bangladesh Soc Anaesthesiologists. 2009;22(2):72–7.

    Article 

    Google Scholar
     

  • Gil-Perotin S, Ramirez P, Marti V, Sahuquillo JM, Gonzalez E, Calleja I, et al. Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. Crit Care. 2012;16(3):1–9.

    Article 

    Google Scholar
     

  • Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15(2):167–93.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785–96.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • van Duin D, Perez F, Rudin SD, Cober E, Hanrahan J, Ziegler J, et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother. 2014;58(7):4035–41.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gominet M, Compain F, Beloin C, Lebeaux D. Central venous catheters and biofilms: where do we stand in 2017? Apmis. 2017;125(4):365–75.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75(2):115–20.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60(9):1295–303.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–50.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Van Duin D, Doi Y, Commentary. Outbreak of Colistin-Resistant, carbapenemase-producing Klebsiella pneumoniae: are we at the end of the Road? J Clin Microbiol. 2015;53(10):3116–7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gelbicova T, Kolackova I, Krutova M, Karpiskova R. The emergence of mcr-1-mediated colistin-resistant Escherichia coli and Klebsiella pneumoniae in domestic and imported turkey meat in the Czech Republic 2017–2018. Folia Microbiol. 2020;65(1):211–6.

    Article 
    CAS 

    Google Scholar
     

  • Doern CD. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol. 2014;52(12):4124–8.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Xu X, Xu L, Yuan G, Wang Y, Qu Y, Zhou M. Synergistic combination of two antimicrobial agents closing each other’s mutant selection windows to prevent antimicrobial resistance. Sci Rep. 2018;8(1):1–7.


    Google Scholar
     

  • Bollenbach T. Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. Curr Opin Microbiol. 2015;27:1–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2012;56(9):4856–61.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Mitchison DA. Prevention of drug resistance by combined drug treatment of tuberculosis. Antibiotic Resist. 2012:87–98.

  • Kerantzas CA, Jacobs WR Jr. Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application. MBio. 2017;8(2):e01586–16.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Caballero J, Rello J. Combination antibiotic therapy for community-acquired pneumonia. Ann Intensiv Care. 2011;1(1):1–7.

    Article 

    Google Scholar
     

  • Zhou A, Kang TM, Yuan J, Beppler C, Nguyen C, Mao Z, et al. Synergistic interactions of vancomycin with different antibiotics against Escherichia coli: trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type E. coli. Antimicrob Agents Chemother. 2015;59(1):276–81.

    Article 
    PubMed 

    Google Scholar
     

  • Drusano GL, Neely M, Van Guilder M, Schumitzky A, Brown D, Fikes S, et al. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLoS ONE. 2014;9(7):e101311.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Eliopoulos GM, Moellering RC Jr. Antibiotic synergism and antimicrobial combinations in clinical infections George. Rev Infect Dis. 1982;4(2):282–93.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Chi H, Holo H. Synergistic antimicrobial activity between the broad spectrum bacteriocin garvicin KS and nisin, farnesol and polymyxin B against gram-positive and gram-negative bacteria. Curr Microbiol. 2018;75:272–7.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol. 2009;12(5):476–81.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tzouvelekis L, Markogiannakis A, Psichogiou M, Tassios P, Daikos G. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682–707.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56(4):2108–13.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kontopidou F, Giamarellou H, Katerelos P, Maragos A, Kioumis I, Trikka-Graphakos E, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect. 2014;20(2):O117–O23.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tallarida RJ. Quantitative methods for assessing drug synergism. Genes & cancer. 2011;2(11):1003–8.

    Article 

    Google Scholar
     

  • Gunnison J, Shevky M, Bruff J, Coleman V, Jawetz E. Studies on antibiotic synergism and antagonism: the effect in vitro of combinations of antibiotics on bacteria of varying resistance to single antibiotics. J Bacteriol. 1953;66(2):150–8.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chin N-X, Neu HC. Synergy of azlocillin with aminoglycosides. J Antimicrob Chemother. 1983;11(supplB):33–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tateda K, Ishii Y, Matsumoto T, Yamaguchi K. Break-point checkerboard plate’for screening of appropriate antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa. Scand J Infect Dis. 2006;38(4):268–72.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Yu L, Zhang J, Fu Y, Zhao Y, Wang Y, Zhao J, et al. Synergetic effects of combined treatment of colistin with meropenem or amikacin on carbapenem-resistant Klebsiella pneumoniae in vitro. Front Cell Infect Microbiol. 2019;9:422.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kilic U, Koroglu M, Olmez M, Altindis M. Investigation of the in vitro effectiveness of aztreonam/avibactam, colistin/apramycin, and meropenem/apramycin combinations against carbapenemase-producing, extensively drug-resistant Klebsiella pneumoniae strains. Microb Drug Resist. 2020;26(11):1291–7.

    Article 
    CAS 

    Google Scholar
     

  • Erdem F, Abulaila A, Aktas Z, Oncul O. In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains. Antimicrob Resist Infect Control. 2020;9(1):1–9.

    Article 

    Google Scholar
     

  • Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev anti-infective Therapy. 2013;11(2):159–77.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Goel A, Gupta V, Singhal L, Palta S, Chander J. In vitro evaluation of antibiotic synergy for carbapenem-resistant Klebsiella pneumoniae clinical isolates. Indian J Med Res. 2021;154(3):520–6.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Dhandapani S, Sistla S, Gunalan A, Manoharan M, Sugumar M, Sastry AS. In-vitro synergistic activity of colistin and meropenem against clinical isolates of carbapenem resistant E. coli and Klebsiella pneumoniae by checkerboard method. Ind J Med Microbiol. 2021;39(1):6–10.

    Article 
    CAS 

    Google Scholar
     

  • Daoud Z, Mansour N, Masri K. Synergistic combination of carbapenems and colistin against P. aeruginosa and A. baumannii. Open J Med Microbiol. 2013;2013.

  • Wang Y, Li C, Wang J, Bai N, Zhang H, Chi Y, et al. The efficacy of Colistin combined with amikacin or levofloxacin against Pseudomonas aeruginosa Biofilm infection. Microbiol Spectr. 2022;10(5):e01468–22.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Klinger-Strobel M, Stein C, Forstner C, Makarewicz O, Pletz MW. Effects of colistin on biofilm matrices of Escherichia coli and Staphylococcus aureus. Int J Antimicrob Agents. 2017;49(4):472–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Li J, Nation RL, Kaye KS. Polymyxin antibiotics: from laboratory bench to bedside. Springer; 2019.

  • Weinstein MP, Limbago B, Patel J, Mathers A, Campeau S, Mazzulli T, et al. M100 performance standards for antimicrobial susceptibility testing. CLSI. 2018;27:210–4.


    Google Scholar
     

  • Kahlmeter G, Brown D, Goldstein F, MacGowan A, Mouton J, Odenholt I, et al. European Committee on Antimicrobial susceptibility testing (EUCAST) technical notes on antimicrobial susceptibility testing. Wiley Online Library; 2006. pp. 501–3.

  • Bardbari AM, Arabestani MR, Karami M, Keramat F, Aghazadeh H, Alikhani MY, et al. Highly synergistic activity of melittin with imipenem and colistin in biofilm inhibition against multidrug-resistant strong biofilm producer strains of Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 2018;37(3):443–54.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Geladari A, Simitsopoulou M, Antachopoulos C, Roilides E. Dose-dependent synergistic interactions of colistin with rifampin, meropenem, and tigecycline against carbapenem-resistant Klebsiella pneumoniae biofilms. Antimicrob Agents Chemother. 2019;63(3):e02357–18.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Leber AL. Clinical microbiology procedures handbook. John Wiley & Sons; 2020.



  • Source link